- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Reimbursement of orphan drugs in Belgium: what (else) matters? ; volume:9 ; number:1 ; day:12 ; month:9 ; year:2014 ; pages:1-9 ; date:12.2014
Orphanet journal of rare diseases ; 9, Heft 1 (12.9.2014), 1-9, 12.2014
- Creator
-
Picavet, Eline
- Contributor
-
Cassiman, David
Simoens, Steven
SpringerLink (Online service)
- DOI
-
10.1186/s13023-014-0139-z
- URN
-
urn:nbn:de:1111-2016050125647
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Picavet, Eline
- Cassiman, David
- Simoens, Steven
- SpringerLink (Online service)
Other Objects (12)
A systematic review of moral reasons on orphan drug reimbursement
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
We empower what matters
Understanding financial inclusion: What matters and how it matters
A systematic review of moral reasons on orphan drug reimbursement
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
We empower what matters
Understanding financial inclusion: What matters and how it matters
A systematic review of moral reasons on orphan drug reimbursement
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
We empower what matters